You just read:

Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL)

News provided by

Janssen R&D Ireland

Apr 12, 2014, 11:15 ET